In cell and gene therapy workflows, rapid, reproducible and traceable processing and manufacturing are essential for product efficacy. In order to reduce the cost and variability of the manufacturing process, particularly for autologous cell therapies, certain steps within these workflows may benefit from optimized automation.
To help with this, the Gibco™ Cell Therapy Systems (CTS™) Rotea™ system can be used for small-batch cell therapy manufacturing. This closed cell-processing system supports low output volumes (to 5 ml) with high levels of cell recovery and viability and can process intake volumes as low as 50 ml. User-programmable protocols deliver process flexibility, single-use kits provide a closed environment for cells and GMP compatibility supports cell therapy manufacturing workflows.
In this application note, discover more about how the CTS Rotea system can be integrated into multiple common steps within a cell therapy workflow (e.g., cell isolation, washing and concentration of various cell types). In addition to this, you can learn more about the characterization and analysis of T cells following processing with the CTS Rotea system as compared to manual processing methods.
This content was supplied by Thermo Fisher Scientific.PG1966-PJT5547-COL24305-DeNovo-New-Rotea-AppNote-Global-FWR